Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T15:28:03.125Z.
Calculation as of: 2026-10-06T15:28:03.125Z.
Quote observation: 2026-10-06T15:25:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2100d4567e155cb65401b1d64ef1112e8effddeb5d941ccec26242c7dbad22d6
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Orchestra BioMed Holdings, Inc.
Market Cap
$354.49M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$356.36M
Price/OCF Ratio
N/A
TTM Avg
6.69
3Y Avg
6.69
5Y Avg
6.69
Market Cap
$356.50M
Price/OCF Ratio
N/A
TTM Avg
46.02
3Y Avg
35.66
5Y Avg
31.75
Market Cap
$348.59M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Orchestra BioMed Holdings, Inc. (OBIO) | $354.49M | N/A | N/A | N/A | N/A |
| Embecta Corp. (EMBC)vs › | $355.67M | 2.04 | 2.73 | 12.47 | 9.98 |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $356.36M | N/A | 6.69 | 6.69 | 6.69 |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $356.50M | N/A | 46.02 | 35.66 | 31.75 |
| Ocugen, Inc. (OCGN)vs › | $359.46M | N/A | N/A | N/A | N/A |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $348.59M | N/A | N/A | N/A | N/A |
| Opus Genetics, Inc. (IRD)vs › | $365.97M | N/A | N/A | N/A | N/A |
| Agenus Inc. (AGEN)vs › | $342.54M | N/A | 418.54 | 418.54 | 418.54 |
| Canopy Growth Corporation (CGC)vs › | $374.07M | N/A | N/A | N/A | N/A |
| ClearPoint Neuro, Inc. (CLPT)vs › | $334.68M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
